Measles Virus Infection and Immunity in a Suboptimal Vaccination Coverage Setting.
cross-protection
epidemiology
immunity
measles
neutralizing antibody
outbreak
secondary vaccine failure
vaccine hesitancy
vaccine uptake
whole-genome sequencing
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
28 Nov 2019
28 Nov 2019
Historique:
received:
02
11
2019
revised:
23
11
2019
accepted:
26
11
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
epublish
Résumé
Despite efforts to improve surveillance and vaccination coverage, measles virus (MeV) continues to cause outbreaks also in high-income countries. As the reference laboratory of the Veneto Region, Italy, we analyzed changes in population immunity, described measles outbreaks, investigated MeV genetic diversity, and evaluated cross-protection of measles vaccination against MeV epidemic strains. Like most European areas, the Veneto Region has suboptimal measles vaccination coverage and is facing a growing public mistrust of vaccination. A progressive decline of measles vaccine uptake was observed during the last decade in the Veneto Region, leading to immunity gaps in children and young adults. Measles outbreaks were caused by the same MeV genotype B3, D4, and D8 strains that were circulating in other European countries. Eleven cases of measles were observed in immunized subjects. These cases were not associated with particular MeV genotypes nor with mutations in epitopes recognized by neutralizing antibodies. Accordingly, sera from fully vaccinated subjects cross-neutralized epidemic MeV strains, including the genotypes B3, D4, and D8, with the same high efficiency demonstrated against the vaccine strain. In fully vaccinated subjects, high MeV IgG antibody titers persisted up to 30 years following vaccination. These results support the use of the current measles-containing vaccines and strategies to strengthen vaccination.
Identifiants
pubmed: 31795157
pii: vaccines7040199
doi: 10.3390/vaccines7040199
pmc: PMC6963570
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Virol. 2017 May 12;91(11):
pubmed: 28356529
J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
Ann Ig. 2018 Jul-Aug;30(4 Supple 1):1-10
pubmed: 30062373
J Allergy Clin Immunol. 2017 Jun;139(6):1995-1997.e9
pubmed: 28087227
Clin Microbiol Infect. 2019 Jul;25(7):907.e1-907.e6
pubmed: 30502489
Lancet. 2018 Sep 1;392(10149):724
pubmed: 30191821
Vaccine. 2019 Jul 26;37(32):4504-4510
pubmed: 31279563
Lancet Infect Dis. 2018 Oct;18(10):1070-1071
pubmed: 30303103
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):777-9
pubmed: 27117246
J Gen Virol. 2007 Jul;88(Pt 7):2028-34
pubmed: 17554037
Vaccine. 2016 Jul 29;34(35):4166-4171
pubmed: 27372154
Mol Biol Evol. 1987 Jul;4(4):406-25
pubmed: 3447015
Mol Biol Evol. 2005 May;22(5):1208-22
pubmed: 15703242
Clin Infect Dis. 2018 Oct 15;67(9):1315-1319
pubmed: 29878209
Pathog Dis. 2016 Nov;74(8):
pubmed: 27777263
J Infect Dis. 2004 May 1;189 Suppl 1:S123-30
pubmed: 15106101
J Infect Dis. 2015 Nov 15;212(10):1574-8
pubmed: 26153409
Vaccine. 2018 Jun 27;36(28):4001-4003
pubmed: 29793892
J Mol Evol. 2008 Feb;66(2):98-106
pubmed: 18217182
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3053-8
pubmed: 23391734
Clin Infect Dis. 2017 Jul 15;65(2):226-232
pubmed: 28387784
Clin Infect Dis. 2014 May;58(9):1205-10
pubmed: 24585562
Clin Infect Dis. 2018 Apr 3;66(8):1270-1275
pubmed: 29228134
Vaccine. 2017 Aug 24;35(36):4673-4680
pubmed: 28757057
Clin Infect Dis. 2019 May 06;:null
pubmed: 31056637
Mol Biol Evol. 2013 May;30(5):1196-205
pubmed: 23420840
Ann Ig. 2019 Mar-Apr;31(2 Supple 1):36-44
pubmed: 30994162
Mol Biol Evol. 2018 Mar 1;35(3):773-777
pubmed: 29301006
J Infect Dis. 2011 Jul;204 Suppl 1:S514-23
pubmed: 21666208
Vaccine. 2018 Jan 25;36(4):507-513
pubmed: 29269156
Sci Transl Med. 2015 Sep 30;7(307):307ra154
pubmed: 26424569
Euro Surveill. 2018 Jul;23(30):
pubmed: 30064543
Viruses. 2016 Aug 02;8(8):
pubmed: 27490564
Health Syst Transit. 2012;14(1):i-xix, 1-138
pubmed: 22575766
Lancet Infect Dis. 2017 Oct;17(10):1089-1097
pubmed: 28807627
J Exp Med. 2019 Sep 2;216(9):2057-2070
pubmed: 31270247
Lancet Infect Dis. 2018 Oct;18(10):1060-1061
pubmed: 30303095
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
J Virol. 2005 Sep;79(17):11547-51
pubmed: 16103210
Vaccine. 2011 Oct 19;29(45):7883-95
pubmed: 21875636
Lancet. 2017 Dec 2;390(10111):2490-2502
pubmed: 28673424
Expert Rev Vaccines. 2019 Jan;18(1):75-87
pubmed: 30585753